Is the recommended minimum dose of anti-D adequate considering the rise in obesity?
Regan
F A M
FA
Naftalin
J
J
Springer
V
V
Paterson-Brown
S
S
D015992:Body Mass Index; D004306:Dose-Response Relationship, Immunologic; D004899:Erythroblastosis, Fetal / Q000276:immunology / Q000517:prevention & control*; D004912:Erythrocytes; D005260:Female; D005331:Fetomaternal Transfusion / Q000276:immunology; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage*; D007518:Isoantibodies / Q000008:administration & dosage / Q000276:immunology*; D009765:Obesity / Q000150:complications* / Q000276:immunology; D011247:Pregnancy; D012204:Rh-Hr Blood-Group System / Q000276:immunology; D018029:Rho(D) Immune Globulin / Q000008:administration & dosage*
D007155:Immunologic Factors; D007518:Isoantibodies; C061961:RHO(D) antibody; D012204:Rh-Hr Blood-Group System; D018029:Rho(D) Immune Globulin; C026410:Rho(D) antigen